Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDNA11 alone or with Keytruda in advanced solid tumors
2023-507536-21-00Phase 2Authorised
- Sponsor
- Medicenna Therapeutics
- Start
- Oct 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of MDNA11 in Nonhematologic neoplasms (2 arms), sponsored by Medicenna Therapeutics. Primary endpoints: Safety and tolerability in dose escalation/evaluation, Recommended dose for expansion and 3 more. Planned start Oct 2024; status: authorised.
02
Drugs
MDNA11
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-507536-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507536-21-00.